Identification of small inhibitory molecules targeting the Bfl-1 Anti-apoptotic protein that alleviates resistance to ABT-737

Journal of Biomolecular Screening

Volumn 19, Issue 7, 2014, Pages 1035-1046

  Mathieu, Anne Laure ^a,g   Sperandio, Olivier ^b,c,d   Pottiez, Virginie ^b   Balzarin, Sophie ^e   Herlédan, Adrien ^b   Elkaïm, Judith O ^c,d   Fogeron, Marie Laure ^f   Piveteau, Catherine ^b   Dassonneville, Sandrine ^b   Deprez, Benoit ^b   Villoutreix, Bruno O ^b,c,d   Bonnefoy, Nathalie ^a,d,e,g   Leroux, Florence ^b,h  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e CENTRE VAL D AURELLE   (France)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITÉ DE LYON   (France)

^h INSTITUT PASTEUR DE LILLE   (France)

Author keywords

apoptosis; Bcl 2; Bfl 1; high throughput screening; protein protein interaction inhibitors

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; BDM 49234; BDM 53787; BDM 56776; BDM 57859; BIM PROTEIN; GAMBOGIC ACID; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG; ABT-737; APOPTOSIS REGULATORY PROTEIN; BCL2-RELATED PROTEIN A1; BIPHENYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MINOR HISTOCOMPATIBILITY ANTIGEN; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BINDING; SULFONAMIDE; VENETOCLAX;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ELECTROPHILICITY; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; LYMPHOMA CELL LINE; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; DRUG DEVELOPMENT; DRUG RESISTANCE; LYMPHOMA; METABOLISM; PROCEDURES; PROTEIN ANALYSIS; SPECTROFLUOROMETRY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; DRUG DISCOVERY; DRUG RESISTANCE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOMA; MINOR HISTOCOMPATIBILITY ANTIGENS; MOLECULAR CONFORMATION; NITROPHENOLS; PIPERAZINES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-BCL-2; SPECTROMETRY, FLUORESCENCE; SULFONAMIDES;

EID: 84904665875     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114534070     Document Type: Article

References (31)

1. Oltersdorf T., Elmore S. W., Shoemaker A. R., et al. An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid Tumours. Nature. 2005 ; 435: 677-681
2. Souers A. J., Leverson J. D., Boghaert E. R., et al. ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity while Sparing Platelets. Nat. Med. 2013 ; 19: 202-208
3. Gandhi L., Camidge D. R., Ribeiro de Oliveira M., et al. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients with Small-Cell Lung Cancer and Other Solid Tumors. J. Clin. Oncol. 2011 ; 29: 909-916
4. Roberts A. W., Seymour J. F., Brown J. R., et al. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients with Relapsed or Refractory Disease. J. Clin. Oncol. 2012 ; 30: 488-496
5. Wilson W. H., O'Connor O. A., Czuczman M. S., et al. Navitoclax, a Targeted High-Affinity Inhibitor of BCL-2, in Lymphoid Malignancies: A Phase 1 Dose-Escalation Study of Safety, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity. Lancet Oncol. 2010 ; 11: 1149-1159
6. Yecies D., Carlson N. E., Deng J., et al. Acquired Resistance to ABT-737 in Lymphoma Cells That Up-Regulate MCL-1 and BFL-1. Blood. 2010 ; 115: 3304-3313
7. Al-Harbi S., Hill B. T., Mazumder S., et al. An Antiapoptotic BCL-2 Family Expression Index Predicts the Response of Chronic Lymphocytic Leukemia to ABT-737. Blood. 2011 ; 118: 3579-3590
8. Vogler M.. BCL2A1: The Underdog in the BCL2 Family. Cell. Death. Differ. 2012 ; 19: 67-74
9. Choi S. S., Park I. C., Yun J. W., et al. A Novel Bcl-2 Related Gene, Bfl-1, Is Overexpressed in Stomach Cancer and Preferentially Expressed in Bone Marrow. Oncogene. 1995 ; 11: 1693-1698
10. Monti S., Savage K. J., Kutok J. L., et al. Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes including One Characterized by Host Inflammatory Response. Blood. 2005 ; 105: 1851-1861
11. Feuerhake F., Kutok J. L., Monti S., et al. NFkappaB Activity, Function, and Target-Gene Signatures in Primary Mediastinal Large B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma Subtypes. Blood. 2005 ; 106: 1392-1399
12. Nagy B., Lundan T., Larramendy M. L., et al. Abnormal Expression of Apoptosis-Related Genes in Haematological Malignancies: Overexpression of MYC Is Poor Prognostic Sign in Mantle Cell Lymphoma. Br. J. Haematol. 2003 ; 120: 434-441
13. Morales A. A., Olsson A., Celsing F., et al. High Expression of bfl-1 Contributes to the Apoptosis Resistant Phenotype in B-Cell Chronic Lymphocytic Leukemia. Int. J. Can. 2005 ; 113: 730-737
14. Olsson A., Norberg M., Okvist A., et al. Upregulation of bfl-1 Is a Potential Mechanism of Chemoresistance in B-Cell Chronic Lymphocytic Leukaemia. Br. J. Can. 2007 ; 97: 769-777
15. Brien G., Trescol-Biemont M. C., Bonnefoy-Berard N.. Downregulation of Bfl-1 Protein Expression Sensitizes Malignant B Cells to Apoptosis. Oncogene. 2007 ; 26: 5828-5832
16. Brien G., Debaud A-L., Bickle M., et al. Characterization of Peptide Aptamers Targeting Bfl-1 Anti-Apoptotic Protein. Biochemistry. 2011 ; 50: 5120-5129
17. Nikolovska-Coleska Z., Wang R., Fang X., et al. Development and Optimization of a Binding Assay for the XIAP BIR3 Domain Using Fluorescence Polarization. Anal. Biochem. 2004 ; 332: 261-273
18. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
19. Garbett N. C., Chaires J. B.. Thermodynamic Studies for Drug Design and Screening. Expert. Opin. Drug. Discov. 2012 ; 7: 299-314
20. Chou T. C.. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006 ; 58: 621-681
21. Morris G. M., Huey R., Lindstrom W., et al. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009 ; 30: 2785-2791
22. Degenhardt K., Sundararajan R., Lindsten T., et al. Bax and Bak Independently Promote Cytochrome C Release from Mitochondria. J. Biol. Chem. 2002 ; 277: 14127-14134
23. Herman M. D., Nyman T., Welin M., et al. Completing the Family Portrait of the Anti-Apoptotic Bcl-2 Proteins: Crystal Structure of Human Bfl-1 in Complex with Bim. FEBS Lett. 2008 ; 582: 3590-3594
24. Kruger D. M., Gohlke H.. DrugScorePPI Webserver: Fast and Accurate in Silico Alanine Scanning for Scoring Protein-Protein Interactions. Nucleic Acids Res. 2010 ; 38: W480 - W486
25. Labbe C. M., Laconde G., Kuenemann M. A., et al. iPPI-DB: A Manually Curated and Interactive Database of Small Non-Peptide Inhibitors of Protein-Protein Interactions. Drug Discov. Today. 2013 ; 18: 958-968
26. Villoutreix B. O., Labbe C. M., Lagorce D., et al. A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors. Curr. Pharm. Des. 2012 ; 18: 4648-4667
27. Lipinski C. A., Lombardo F., Dominy B. W., et al. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug. Deliv. Rev. 2001 ; 46: 3-26
28. Veber D. F., Johnson S. R., Cheng H. Y., et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002 ; 45: 2615-2623
29. Cashman J.R., MacDonald M., Ghirmai S., et al. Inhibition of Bfl-1 with N-aryl Maleimides. Bioorg. Med. Chem. Lett. 2010 ; 20: 6560-6564
30. Zhai D., Godoi P., Sergienko E., et al. High-Throughput Fluorescence Polarization Assay for Chemical Library Screening against Anti-Apoptotic Bcl-2 Family Member Bfl-1. J. Biomol. Screen. 2012 ; 17: 350-360
31. Curpan R. F., Simons P. C., Zhai D., et al. High-Throughput Screen for the Chemical Inhibitors of Antiapoptotic Bcl-2 Family Proteins by Multiplex Flow Cytometry. Assay. Drug. Dev. Technol. 2011 ; 9: 465-474